traditional-medicine-2016_posters-accepted-abstracts

20 / 23

Volume 5, Issue 2 (Suppl) J Tradi Med Clin Natur
ISSN: JTMCN, an open access journal
Page 89
Traditional Medicine 2016
September 14-16, 2016
conferenceseries.com
September 14-16, 2016 Amsterdam, Netherlands
6th International Conference and Exhibition on
Traditional & Alternative Medicine
J Tradi Med Clin Natur 2016, 5:2 (Suppl)
Herbal decoction-based combination therapy of Chinese hepatic cell carcinoma:Aretrospective clinical
study
Y L Gong1, G M Lv2, L L Zhu3, R Q Wei4, H J Wan1, M Hu5, Ch J Tao6, S K Wang7 and C F Niu1
1Nanjing University, China
2Jiangsu Jiankang Vocational College, China
3Southeast University, China
4Nanjing Medical University, China
5Liyang 1st People's Hospital, China
6Shanghai Eastern Hepatobiliary Surgery Hospital, China
7Zhangjiagang 1st People's Hospital, China
Aim: The main of the study is to contribute a humble effort to promote Chinese traditional medicine, a retrospective clinical study
was performed to assess the efficacy of Chinese herbal decoction-based combination treatment of hepatic cell carcinoma (HCC).
Methods: 42 hospitalized patients with histologically confirmed HCC from Jan 2012 to Dec 2014 were selected randomly, including
22 cases in the control group for conventional therapy of surgical resection and/or chemo-radiotherapy as usual; and 20 patients in
the study group for combined treatment of “warm and removing” decoction (WRD) on the basis of standard care. In the meantime,
evaluation of clinical characteristics and quality of life was assessed.
Results: There was a significant difference (P<0.05) in the comparison of AFP (alpha feto protein)/ALT (alanine transaminase) level
between control and study groups. The DCR (disease control rate) was 43% in the study group compared with 34% in the control
group. Three-month PFS (Progression-Free-Survival) and TTP (Time-to-Progression) rates were 60%, 35% for WRD patients and
45%, 40% for control patients, respectively. The retrospective clinical study showed no overall survival (OS) benefit for HCC patients
treated with WRD compared with control, while the QOL (quality of life) evaluation seemed to predict survival better for WRD
patients than that for control patients.
Conclusions: Chinese herbs in the WRD may have the ability of increasing cellular immunity and reducing surgical or chemo-radio-
therapeutic lesions. Chinese herbs of WRD might be an additional choice with its better benefits and tolerability in the combination
treatment of HCC.